Cyanotech Narrows Losses, Boosts Sales Amidst Liquidity Concerns

TL;DR

**CYAND's quarterly profit is a mirage; the company is still bleeding cash and relying on related-party lifelines, making it a risky bet.**

AI Summary

CYANOTECH CORP (CYAND) reported a significant turnaround in net income for the three months ended September 30, 2025, achieving a net income of $1,000 compared to a net loss of $1,150,000 in the prior year period. This improvement was driven by a 19.3% increase in net sales, reaching $6,976,000 from $5,845,000, and a substantial rise in gross profit to $2,393,000 from $1,479,000. For the six months ended September 30, 2025, the company still posted a net loss of $925,000, though this was an improvement from the $2,352,000 net loss in the same period of 2024. The company's working capital decreased to $39,000 as of September 30, 2025, from $302,000 as of March 31, 2025. CYANOTECH CORP continues to face liquidity challenges, evidenced by a related-party line of credit increasing to $4,200,000 from $3,000,000, and covenant violations on its bank debt, though waivers were obtained. The company is implementing cost-saving initiatives, including slowing inventory production and maintaining reduced headcount, to address cash flow challenges and improve its financial position.

Why It Matters

This filing reveals a mixed bag for investors: while Cyanotech showed impressive quarterly net income growth and sales recovery, its ongoing liquidity issues and reliance on related-party financing signal underlying instability. The company's ability to secure waivers for debt covenant violations with First Foundation Bank is a temporary reprieve, but the shrinking working capital to $39,000 from $302,000 indicates persistent financial strain. Competitors in the microalgae and dietary supplements market, such as those producing spirulina and astaxanthin, might see this as an opportunity if Cyanotech's financial health doesn't stabilize, potentially impacting market share and pricing power. Employees face uncertainty given the reduced headcount and furloughs, while customers could see supply chain risks if production issues persist.

Risk Assessment

Risk Level: high — The company explicitly states that conditions 'raise substantial doubt about the Company's ability to continue as a going concern.' This is supported by sustained operating losses and negative cash flows from operations, coupled with non-compliance with two debt covenant requirements as of March 31, 2025, and 2024, for which waivers were obtained. The working capital decreased significantly to $39,000 as of September 30, 2025, from $302,000 as of March 31, 2025, further highlighting liquidity concerns.

Analyst Insight

Investors should exercise extreme caution and consider avoiding CYAND given the explicit 'going concern' warning and reliance on related-party debt. Monitor future filings closely for sustained profitability, improved working capital, and reduced dependence on waivers for debt covenants before considering any investment.

Financial Highlights

debt To Equity

1.98

revenue

$6,976,000

operating Margin

2.7%

total Assets

$24,027,000

total Debt

$15,962,000

net Income

$1,000

eps

$0.00

gross Margin

34.3%

cash Position

$649,000

revenue Growth

+19.3%

Key Numbers

• $1,000 — Net Income (for the three months ended September 30, 2025, a significant improvement from a $1,150,000 net loss in the prior year.)
• $6,976,000 — Net Sales (for the three months ended September 30, 2025, up 19.3% from $5,845,000 in the prior year.)
• $925,000 — Net Loss (for the six months ended September 30, 2025, an improvement from a $2,352,000 net loss in the prior year.)
• $39,000 — Working Capital (as of September 30, 2025, a decrease from $302,000 as of March 31, 2025, indicating reduced liquidity.)
• $4,200,000 — Related-Party Line of Credit (outstanding as of September 30, 2025, an increase from $3,000,000 as of March 31, 2025, showing increased reliance on related-party financing.)
• 7,392,243 — Common Shares Outstanding (as of November 1, 2025, indicating potential dilution from prior periods.)
• $649,000 — Cash (as of September 30, 2025, an increase from $257,000 as of March 31, 2025, but still a low amount for operations.)
• $2,809,000 — Long-term Debt to Bank (outstanding as of September 30, 2025, with covenant violations noted.)

Key Players & Entities

• CYANOTECH CORP (company) — registrant
• First Foundation Bank (company) — lender
• Nutrex Hawaii, Inc. (company) — wholly owned subsidiary
• $1,000 (dollar_amount) — net income for Q3 2025
• $1,150,000 (dollar_amount) — net loss for Q3 2024
• $6,976,000 (dollar_amount) — net sales for Q3 2025
• $5,845,000 (dollar_amount) — net sales for Q3 2024
• $925,000 (dollar_amount) — net loss for six months ended September 30, 2025
• $2,352,000 (dollar_amount) — net loss for six months ended September 30, 2024
• $4,200,000 (dollar_amount) — outstanding on related-party Revolver as of September 30, 2025

FAQ

Risk Factors

• Liquidity and Going Concern [high — financial]: The company's working capital decreased significantly to $39,000 as of September 30, 2025, from $302,000 as of March 31, 2025. This, coupled with an increasing reliance on a related-party line of credit ($4,200,000 outstanding as of September 30, 2025, up from $3,000,000), and covenant violations on bank debt (though waivers were obtained), indicates substantial liquidity challenges. The company's ability to continue as a going concern is dependent on its ability to generate sufficient cash flow from operations and secure additional financing.
• Debt Covenant Violations [high — financial]: CYANOTECH CORP has experienced covenant violations on its bank debt. While waivers were obtained, this indicates a precarious financial position and potential for future defaults if financial performance does not improve or if lenders withdraw their support. The outstanding long-term debt to bank was $2,809,000 as of September 30, 2025.
• Inventory Management and Production Slowdown [medium — operational]: The company is implementing cost-saving initiatives, including slowing inventory production. While intended to address cash flow challenges, a prolonged slowdown could impact future sales if demand increases and inventory levels are insufficient. Inventories were $8,378,000 as of September 30, 2025.
• Reliance on Related-Party Financing [medium — financial]: The outstanding balance on the related-party line of credit increased to $4,200,000 as of September 30, 2025, from $3,000,000 as of March 31, 2025. This growing dependence on related-party financing could pose risks if the terms become unfavorable or if the related party is unable to continue providing support.
• Reduced Headcount [low — operational]: The company is maintaining reduced headcount as part of its cost-saving initiatives. While this can improve short-term profitability, it may impact the company's ability to scale operations or respond to increased demand in the future.

Industry Context

The microalgae industry, where Cyanotech operates, is characterized by niche markets for nutritional supplements (like spirulina and astaxanthin) and potentially for biofuels or other industrial applications. Growth is driven by increasing consumer demand for natural health products and advancements in cultivation technology. However, the industry can be competitive, with companies facing challenges related to production costs, scalability, and regulatory approvals for new applications.

Regulatory Implications

As a producer of nutritional supplements, Cyanotech is subject to regulations by bodies like the FDA regarding product safety, labeling, and manufacturing practices (cGMP). Any failure to comply can result in product recalls, fines, or reputational damage. The company's financial distress could also attract increased scrutiny from regulatory bodies concerning its operational stability and disclosures.

What Investors Should Do

1. Monitor cash flow generation and working capital trends closely.
2. Assess the sustainability of the recent quarterly net income improvement.
3. Evaluate the terms and risks associated with related-party financing.
4. Understand the implications of debt covenant violations and waivers.

Key Dates

• 2025-09-30: End of Second Fiscal Quarter — Reporting period for the 10-Q, showing a significant improvement in net income for the quarter but continued net loss for the six-month period. Working capital decreased, and related-party debt increased.
• 2025-03-31: End of First Fiscal Quarter / Previous Fiscal Year End — Comparison point for working capital and related-party line of credit, showing a substantial decrease in working capital and an increase in related-party financing.

Glossary

Working Capital

The difference between a company's current assets and current liabilities. It is a measure of both a company's operational efficiency and its short-term financial health. (A significant decrease in working capital to $39,000 indicates potential liquidity challenges for CYANOTECH CORP.)

Line of Credit - Related Party

A loan facility provided by an entity that has a close relationship with the borrower, such as a parent company, subsidiary, or major shareholder. (The increase in this line of credit to $4,200,000 highlights CYANOTECH CORP's reliance on financing from related parties.)

Covenant Violations

Breaches of terms or conditions set forth in a loan agreement or other contract. For debt, these typically relate to financial ratios or performance metrics. (Violations on bank debt, even with waivers, signal financial distress and potential future issues for CYANOTECH CORP.)

Accumulated Deficit

The cumulative net losses of a company since its inception, less any net gains. It represents a deficit in retained earnings. (CYANOTECH CORP has a substantial accumulated deficit of $27,029,000 as of September 30, 2025, indicating a history of unprofitability.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. If there are substantial doubts about this, it must be disclosed. (The company's financial condition, particularly its liquidity, raises questions about its ability to continue as a going concern.)

Year-Over-Year Comparison

Compared to the prior year period, CYANOTECH CORP has demonstrated a significant turnaround in quarterly net income, moving from a $1,150,000 loss to a $1,000 profit, driven by a 19.3% increase in net sales and improved gross profit margins. However, for the six-month period, the company still reports a net loss of $925,000, albeit an improvement from the $2,352,000 loss last year. Key financial health indicators show deterioration, with working capital decreasing substantially from $302,000 to $39,000, and an increased reliance on related-party financing, evidenced by the line of credit growing from $3,000,000 to $4,200,000.

Filing Documents

• cyan20250930_10q.htm (10-Q) — 1112KB
• ex_883364.htm (EX-31.1) — 12KB
• ex_883365.htm (EX-31.2) — 13KB
• ex_883366.htm (EX-32) — 6KB
• ex_883367.htm (EX-99.1) — 150KB
• logo991.jpg (GRAPHIC) — 6KB
• 0001437749-25-034093.txt ( ) — 5984KB
• cyan-20250930.xsd (EX-101.SCH) — 53KB
• cyan-20250930_cal.xml (EX-101.CAL) — 42KB
• cyan-20250930_def.xml (EX-101.DEF) — 353KB
• cyan-20250930_lab.xml (EX-101.LAB) — 331KB
• cyan-20250930_pre.xml (EX-101.PRE) — 389KB
• cyan20250930_10q_htm.xml (XML) — 883KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 4 Condensed Consolidated Balance Sheets as of September 30, 2025 and March 31, 2025 (unaudited) 4 Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Stockholders ' Equity for the three and six months ended September 30, 2025 and 2024 (unaudited) 6 Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2025 and 2024 (unaudited) 8 Notes to Condensed Consolidated Financial Statements (unaudited) 9 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 22 Item 4.

Controls and Procedures

Controls and Procedures 28

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A

Risk Factors

Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults upon Senior Securities 29 Item 5. Other Information 29 Item 6. Exhibits 30

SIGNATURES

SIGNATURES 31 3 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CYANOTECH CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share data) (Unaudited) September 30, 2025 March 31, 2025 ASSETS Current assets: Cash $ 649 $ 257 Accounts receivable, net of allowance for credit losses of $ 9 as of September 30, 2025 and $ 16 as of March 31, 2025 2,354 1,953 Inventories 8,378 7,788 Prepaid expenses and other current assets 550 547 Total current assets 11,931 10,545 Equipment and leasehold improvements, net 8,353 8,927 Operating lease right-of-use assets, net 3,632 3,902 Other assets 111 116 Total assets $ 24,027 $ 23,490 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,971 $ 2,217 Accrued expenses 920 715 Customer deposits 67 110 Operating lease obligations, current portion 576 555 Short-term debt - bank 370 760 Line of credit - related party 4,200 3,000 Current maturities of long-term debt 2,788 2,886 Total current liabilities 11,892 10,243 Long-term debt - related party 1,000 1,000 Long-term operating lease obligations 3,070 3,363 Total liabilities 15,962 14,606 Commitments and contingencies Stockholders' equity Preferred stock of $ 0.01 par value, 10,000,000 shares authorized; no shares issued and outstanding - - Common stock of $ 0.02 par value, 50,000,000 shares authorized; 7,392,243 shares at September 30, 2025 and 7,199,908 shares at March 31, 2025 issued and outstanding 148 144 Additional paid-in capital 34,946 34,844 Accumulated deficit ( 27,029 ) ( 26,104 ) Total stockholders' equity 8,065 8,884 Total liabilities and stockholders' equity $ 24,027 $ 23,490 See accompanying notes to condensed consolidated financial statements 4 Table of Contents CYANOTECH CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands except per share amounts) (Unaudited) Three Months Ended September 30, Six Months Ended September 30, 2025 2024 2025 2024

View Full Filing

View this 10-Q filing on SEC EDGAR